NCT05993299Recruitment Completed
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
GlaxoSmithKlinePhase 2ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Neoplasms
- Drug/Device/Intervention
- Letetresgene autoleucel
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- GlaxoSmithKline
- Location
- Pittsburgh,Dallas,Milwaukee,Montreal,Amsterdam,London, Canada,Netherlands,United Kingdom,United States of America
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Dec 31, 2019
- End date
- Jul 01, 2024
- Enrollment
- 7 participants
Primary outcome
Overall Response Rate (ORR)
Summary
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in
 participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.
ICD-10 classifications
NeoplasmsIn situ neoplasmsPersonal history of other neoplasmsBenign neoplasmsMalignant neoplasms
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05993299
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05993299 through Pure Global AI's free database. This Phase 2 trial is sponsored by GlaxoSmithKline and is currently Recruitment Completed. The study focuses on Neoplasms. Target enrollment is 7 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.